Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision psychiatry: celecoxib for immuno‑metabolic major depressive disorder
2024-513907-15-01Phase 3Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Celecoxib adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Change in depressive symptom severity (IDS total score). Started Oct 2024; status: completed.
02
Drugs
celecoxib
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-513907-15-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513907-15-01.